LUCIUS 卢修斯 吉非替尼 Gefitinib非小细胞肺癌

吉非替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Gefitinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

非小细胞肺癌

Each film-coaled tablet contains Gefitimib 250 mg.

Indicalion

LaciGefiis a tyrosine kinase inhibitor indicated

LUCIUS

forthe first-line treatment of patients with

PHARMACEUTICALS

metastatic non-small cell lung e
whose tumors have epidermal growth lactor
receptor (EGFR Laves 101 ..
(L858R) substitution mutations as detected by an

Gefitinib Tablets

Fimitation of Lise: Safety and efficacy of LuciGefi

LuciGefi 250mg

have not been established in patients w hose tumors

FDA批准

have EGrK mutations otber thas exon 19 deletione
or exon 21(L858R) substitution mutnfions
with or without food.
ose is 250 mg orlly, once daily

30 Tablets

Storage: in a dry place and store at 20C to 25°C
adry piacs

Haring
Keep medicine out of reach of Children. Do not
Adouonister LueiGefi during Pregnancy and
PLEASE SEEPACKAGEINSER
Manufactured and Marketed by:

权威认证

LUCIUS

Thonemang village. Xaythany district
Vientiane Capital, Laos
Warning: To be sold by retarl on prescrption
of registered physicians only, and as directed

Rx Only

口碑质量

适应症:
LuciGefi是一种酪氨酸激酶抑制剂,适用于一线治疗转移
性非小细胞肺癌(NSCLC)患者,这些患者的肿瘤经FDA
批准的检测检测出存在表皮生长因子受体(EGFR)外显子
19缺失或外显子21(L858R)替代突变。
推荐剂量:
每日一次,每次口服250mg,可与食物同服或单独服用。